1084-12-4

Basic information

• Product Name: N-(5-bromopyridin-3-yl)benzenesulfonamide
• Synonyms: N-(5-bromopyridin-3-yl)benzenesulfonamide;N-(5-BroMo-3-pyridyl)benzenesulfonaMide, 96%;N-(5-bromo-3-pyridinyl)Benzenesulfonamide
• CAS NO: 1084-12-4
• Molecular Formula: C₁₁H₉BrN₂O₂S
• Molecular Weight: 313.17036
• Mol File: 1084-12-4.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N-(5-bromopyridin-3-yl)benzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(5-bromopyridin-3-yl)benzenesulfonamide(1084-12-4)
• EPA Substance Registry System: N-(5-bromopyridin-3-yl)benzenesulfonamide(1084-12-4)

Safety Data

• Hazardous Substances Data: 1084-12-4(Hazardous Substances Data)

Usage

General Description

N-(5-bromopyridin-3-yl)benzenesulfonamide is a chemical compound that consists of a sulfonamide group attached to a benzene ring, with a 5-bromopyridin-3-yl group attached to the nitrogen atom of the sulfonamide. N-(5-bromopyridin-3-yl)benzenesulfonamide is commonly used as a building block in organic synthesis and drug development. It has been investigated for its potential antifungal, antiviral, and anti-inflammatory properties. Its chemical structure and reactivity make it useful for creating new molecules with desirable biological activities. Furthermore, its bromopyridine moiety can serve as a handle for various chemical modifications, making it a versatile starting material for the synthesis of diverse compounds with potential pharmaceutical applications.

Upstream product

• 98-09-9 benzenesulfonyl chloride 
• 13535-01-8 3-amino-5-bromopyridine 
• 1192749-74-8 N-(5-bromopyridin-3-yl)-N-(phenylsulfonyl)benzenesulfonamide 

Downstream Products

• 1083326-28-6 N-(5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-yl)-benzenesulfonamide 
• 1198803-16-5 N-{5-[4-amino-1-(phenylsulfonyl)-1H-indazol-6-yl]-3-pyridinyl}benzenesulfonamide 
• 1276109-91-1 N-(5-(3-pyridyl)pyridin-3-yl)benzenesulfonamide 
• 1276109-93-3 N-(5-(4-pyridyl)pyridin-3-yl)benzenesulfonamide 
• 1276110-12-3 N-(5-(3-(2H-tetrazol-5-yl)imidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)-benzenesulfonamide 
• 1276110-15-6 N-(5-(3-phenylimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1276110-06-5 ethyl 6-(5-(phenylsulfonamido)pyridin-3-yl)imidazo[1,2-a]-pyridine-3-carboxylate 
• 1276110-04-3 N-(5-(3-cyanoimidazo[1,2-a]pyridin-6-yl)pyridin-3-yl)benzenesulfonamide 
• 1092565-37-1 N-[5-(8-chloro-1,5-naphthyridin-2-yl)-3-pyridinyl]benzenesulfonamide 
• 1092565-32-6 N-{5-[8-(4-pyridinyl)-1,5-naphthyridin-2-yl]-3-pyridinyl}benzenesulfonamide 
• 1092565-40-6 N-{5-[8-(4-morpholinyl)-1,5-naphthyridin-2-yl]-3-pyridinyl}benzenesulfonamide 
• 1092565-33-7 N-(5-{8-[3-(methylsulfonyl)phenyl]-1,5-naphthyridin-2-yl}-3-pyridinyl)benzenesulfonamide 
• 1092565-41-7 N-{5-[8-(4-hydroxy-1-piperidinyl)-1,5-naphthyridin-2-yl]-3-pyridinyl}benzenesulfonamide 
• 1092565-36-0 N-[5-(8-{4-[(dimethylamino)methyl]phenyl}-1,5-naphthyridin-2-yl)-3-pyridinyl]benzenesulfonamide 

Relevant articles and documents

Prospective evaluation and success of a machine learning hit-to-lead drug development program against phosphatidylinositol 3-kinase α

As a result of the rapidly increasing cost of drug development, efficient methods for early identification of compounds with a high probability of clinical success are needed. Herein, we describe a cheminformatics protocol which dramatically increases quality candidate identification and should reduce the attrition rate of compounds entering the clinic, increasing the cost-effectiveness of drug development. Against the oncology target phosphatidylinositol 3-kinase α, all five compounds synthesized from the protocol were found to have low nanomolar activity. We therefore propose that our protocol can be used as a tool for reducing the synthetic burden required for hit-to-lead optimization.

Discovery of a Novel Series of 7-Azaindole Scaffold Derivatives as PI3K Inhibitors with Potent Activity

The phosphoinositide 3-kinase (PI3K) inhibitors potently inhibit the signaling pathway of PI3K/AKT/mTOR, which provides a promising new approach for the molecularly targeted cancer therapy. In this work, a novel series of 7-azaindole scaffold derivatives was discovered by the fragment-based growing strategy. The structure-activity relationship profiles identified that the 7-azaindole scaffold derivatives exhibit potent activity against PI3K at molecular and cellular levels as well as cell proliferation in a panel of human tumor cells.

NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.